A review on thromboangiitis obliterans pathophysiology: Thrombosis and angiitis, which is to blame?

Vascular

Volumn 19, Issue 3, 2011, Pages 141-153

  Fazeli, Bahare ^a   Rezaee, Seyed Abdolrahim ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Buerger's disease; Neurogenic inflammation; Smoking; Thromboangiitis obliterans; Thrombosis; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; BACTERIUM LIPOPOLYSACCHARIDE; BERAPROST; CD40 ANTIGEN; CD40 LIGAND; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HOMOCYSTEINE; ILOPROST; INDOLEAMINE 2,3 DIOXYGENASE; INTERCELLULAR ADHESION MOLECULE 1; NICOTINE; NIFEDIPINE; NITRIC OXIDE; PADGEM PROTEIN; PROTEIN S 100; PURINERGIC P2Y12 RECEPTOR; REACTIVE OXYGEN METABOLITE; SARPOGRELATE; SEROTONIN; STREPTOKINASE; SUBSTANCE P; THROMBOPOIETIN; THROMBOXANE A2; TICLOPIDINE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; BUERGER DISEASE; CD4+ T LYMPHOCYTE; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; GENETIC RISK; HUMAN; LEUKOCYTOSIS; LOW DRUG DOSE; MENTAL STRESS; MOUTH HYGIENE; NEUROGENIC INFLAMMATION; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SMOKING; SOCIAL STATUS; THROMBOCYTE; THROMBOCYTE ACTIVATION; TOBACCO; VASCULITIS; VASOSPASM; ADVERSE EFFECTS; AGE; COMPLICATION; FEMALE; MALE; RISK FACTOR; THROMBOANGIITIS OBLITERANS; THROMBOSIS;

AGE FACTORS; FEMALE; HUMANS; MALE; RISK FACTORS; SEX FACTORS; SMOKING; THROMBOANGIITIS OBLITERANS; THROMBOSIS; VASCULITIS;

EID: 84857710797     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: 10.1258/vasc.2010.ra0045     Document Type: Review

References (133)

1. Olin JW, Shih A. Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol 2006;18:18-24 (Pubitemid 43740401)
2. Shionoya S. Buerger's disease: diagnosis and management. Cardiovasc Surg 1993;1:207-14
3. Puéchal X, Fiessinger JN. Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist. Rheumatology (Oxford) 2007;46:192-9 (Pubitemid 46189775)
4. Joras M, Poredos P, Fras Z. Endothelial dysfunction in Buerger's disease and its relation to markers of inflammation. Eur J Clin Invest 2006;36:376-82 (Pubitemid 43742694)
5. Halacheva K, Gulubova MV, Manolova I, Petkov D. Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochem 2002;104:177-84 (Pubitemid 34606364)
6. Fazeli B. Buerger's disease as an indicator of socioeconomic development in different societies, a cross-sectional descriptive study in the North-East of Iran. Arch Med Sci 2010;6:343-7
7. Williams G. Recent views on Buerger's disease. J Clin Pathol 1969;22:573-8
8. Sato T, Tsujino I, Ikeda D, Ieko M, Nishimura M. Trousseau's syndrome associated with tissue factor produced by pulmonary adenocarcinoma. Thorax 2006;61:1009-10 (Pubitemid 44787173)
9. Regina ML, Gasparyan AY, Orlandini F, Prisco D. Behçet's disease as a model of venous thrombosis. Open Cardiovasc Med J 2010;4:71-7
10. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008;67:1656-62
11. Guiducci S, Giacomelli R, Cerinic MM. Vascular complications of scleroderma. Autoimmun Rev 2007;6:520-3 (Pubitemid 47374612)
12. Cocco G, Gasparyan AY. Myocardial ischemia in Wegener's granulomatosis: coronary atherosclerosis versus vasculitis. Open Cardiovasc Med J 2010;4:57-62
13. Li N. Platelet-lymphocyte cross-talk. J Leukoc Biol 2008;83: 1069-78 (Pubitemid 351960338)
14. Wagner DD. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005;25:1321-4 (Pubitemid 40923346)
15. Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun 2002;16:622-53 (Pubitemid 36027055)
16. Tanaka K. Pathology and pathogenesis of Buerger's disease. Int J Cardiol 1998;66(Suppl 1):S237-42 (Pubitemid 29037953)
17. Piazza G, Creager MA. Thromboangiitis obliterans. Circulation 2010;121:1858-61. Review
18. Kobayashi M, Ito M, Nakagawa A, Nishikimi N, Nimura Y. Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans). J Vasc Surg 1999;29:451-8 (Pubitemid 29152267)
19. Lee T, Seo JW, Sumpio BE, Kim SJ. Immunobiologic analysis of arterial tissue in Buerger's disease. Eur J Vasc Endovasc Surg 2003;25:451-7 (Pubitemid 36592465)
20. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32 (Pubitemid 41541790)
21. Sironi M, Clerici M. The hygiene hypothesis: an evolutionary perspective. Microbes Infect 2010;12:421-7
22. Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation 1995;91:2742-7
23. Al-Awadhi AM, AlFadhli SM, Mustafa NY, Sharma PN. Effects of cigarette smoking on hematological parameters and von Willebrand factor functional activity levels in asymptomatic male and female Arab smokers. Med Princ Pract 2008;17: 149-53 (Pubitemid 351301302)
24. Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med 1994;154:164-8 (Pubitemid 24032190)
25. Zervas J, Vayopoulos G, Konstantopoulos K, et al. HLA antigens in Burger's disease. Clin Rheumatol 1991;10:434-6
26. Aerbajinai W, Tsuchiya T, Kimura A, Yasukochi Y, Numano F. HLA class II DNA typing in Buerger's disease. Int J Cardiol 1996;54(Suppl):S197-202
27. Jaini R, Mandal S, Khazanchi RK, Mehra NK. Immunogenetic analysis of Buerger's disease in India. Int J Cardiol 1998;66 (Suppl 1):S283-5 (Pubitemid 29037959)
28. Papa M, Bass A, Adar R, et al. Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex. Surgery 1992;111:527-31
29. Tiwari JL, Terasaki PI. HLA-DR and disease associations. Prog Clin Biol Res 1981;58:151-63
30. Chen Z, Takahashi M, Naruse T, et al. Synergistic contribution of CD14 and HLA loci in the susceptibility to Buerger disease. Hum Genet 2007;122:367-72 (Pubitemid 47616544)
31. Abbas AK, Litchman AH, Pillai S. Cellular and Molecular Immunology. 6th edn. Philadelphia: Saunders Elsevier, 2007:510
32. Ostojic L, Zelenika D, Zotz RB, Sucker C, Ostojic Z, Loncar R. Platelet receptor HPA-1 polymorphism of alphaIIbbeta3 and 807 C/T polymorphism of alpha2beta1 and Buerger's disease. Angiology 2007;58:169-74 (Pubitemid 46669105)
33. Fazeli B, Arshadi H. A plan of group therapy for smoking cessation in patients suffering from Buerger's disease: a case series study in Northeast Iran. Smoking Cessation 2009;4:42-7
34. Lie JT. Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. Arthritis Rheum 1988;31:812-3
35. Lawrence PF, Lund OI, Jimenez JC, Muttalib R. Substitution of smokeless tobacco for cigarettes in Buerger's disease does not prevent limb loss. J Vasc Surg 2008;48:210-2 (Pubitemid 351853317)
36. Joyce JW. Buerger's disease (thromboangiitis obliterans). Rheum Dis Clin North Am 1990;16:463-70 (Pubitemid 20380162)
37. Jiménez-Ruiz CA, Dale LC, Astray Mochales J, Velázquez Buendía L, de Granda Orive I, Guirao García A. Smoking characteristics and cessation in patients with thromboangiitis Obliterans. Monaldi Arch Chest Dis 2006;65:217-21 (Pubitemid 46455210)
38. Mills JL Sr. Buerger's disease in the 21st century: diagnosis, clinical features, and therapy. Semin Vasc Surg 2003;16:179-89. Review
39. Fazeli B, Modaghegh H, Ravrai H, Kazemzadeh G. Thrombophlebitis migrans as a footprint of Buerger's disease: a prospective-descriptive study in north-east of Iran. Clin Rheumatol 2008;27:55-7 (Pubitemid 350182678)
40. Blann AD, Kirkpatrick U, Devine C, Naser S, McCollum CN. The influence of acute smoking on leucocytes, platelets and the endothelium. Atherosclerosis 1998;141:133-9 (Pubitemid 28539424)
41. Casey RG, Joyce M, Roche-Nagle G, Cox D, Bouchier-Hayes DJ. Young male smokers have altered platelets and endothelium that precedes atherosclerosis. J Surg Res 2004;116:227-33 (Pubitemid 38175312)
42. Calvete JJ. On the structure and function of platelet integrin alpha IIb beta 3, the fibrinogen receptor. Proc Soc Exp Biol Med 1995;208:346-60
43. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395-424 (Pubitemid 28411134)
44. Ryan US, Worthington RE. Cell-cell contact mechanisms. Curr Opin Immunol 1992;4:33-7
45. Roncon-Albuquerque R, Serrão P, Vale-Pereira R, Costa-Lima J, Roncon-Albuquerque R Jr. Plasma catecholamines in Buerger's disease: effects of cigarette smoking and surgical sympathectomy. Eur J Vasc Endovasc Surg 2002;24:338-43 (Pubitemid 41079339)
46. Birk AV, Leno E, Robertson HD, Bolotina VM, Szeto HH. Interaction between ATP and catecholamines in stimulation of platelet aggregation. Am J Physiol Heart Circ Physiol 2003;284: H619-25 (Pubitemid 36142890)
47. Olbrich C, Aepfelbacher M, Siess W. Epinephrine potentiates calcium mobilization and activation of protein kinases in platelets stimulated by ADP through a mechanism unrelated to phospholipase C. Cell Signal 1989;1:483-92 (Pubitemid 20031106)
48. Zukowska-Grojec Z, Neuropeptide Y. A novel sympathetic stress hormone and more. Ann N Y Acad Sci 1995;771:219-33 (Pubitemid 26077409)
49. Shanker G, Kontos JL, Eckman DM, Wesley-Farrington D, Sane DC. Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb Thrombolysis 2006;22:213-20 (Pubitemid 44857783)
50. Togna AR, Latina V, Orlando R, Togna GI. Cigarette smoke inhibits adenine nucleotide hydrolysis by human platelets. Platelets 2008;19:537-42
51. Murugappa S, Kunapuli SP. The role of ADP receptors in platelet function. Front Biosci 2006;11:1977-86 (Pubitemid 43253409)
52. Fusegawa Y, Handa S. Platelet aggregation induced by ADP or epinephrine is enhanced in habitual smokers. Thromb Res 2000;97:287-95 (Pubitemid 30089033)
53. Park SK, O'Neill MS, Vokonas PS, et al. Traffic-related particles are associated with elevated homocysteine: the VA normative aging study. Am J Respir Crit Care Med 2008;178:283-9
54. Böhmer AE, Pochmann D, Sarkis JJ. In vitro effect of homocysteine on nucleotide hydrolysis by blood serum from adult rats. Chem Biol Interact 2006;160:159-64 (Pubitemid 43348488)
55. van Guldener C, Stehouwer CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Thromb Hemost 2000;26:281-9
56. Stammler F, Diehm C, Hsu E, Stockinger K, Amendt K. The prevalence of hyperhomocysteinemia in thromboangiitis obliterans. Does homocysteine play a role pathogenetically? Dtsch Med Wochenschr 1996;121:1417-23 (Pubitemid 26385151)
57. Adar R, Papa MZ, Schneiderman J. Thromboangiitis obliterans: an old disease in need of a new look. Int J Cardiol 2000;75 (Suppl 1):S167-70; discussion S171-3
58. Courtney PA, Sharpe PC, Lee RJ. Homocysteine and "Buerger's disease". Postgrad Med J 2002;78:500, 504-5
59. Olin JW, Childs MB, Bartholomew JR, Calabrese LH, Young JR. Anticardiolipin antibodies and homocysteine levels in patients with thromboangiitis obliterans. Arthritis Rheum 1996;39:S-47-S-47
60. Pierce PA, Xie GX, Peroutka SJ, Green PG, Levine JD. 5-Hydroxytryptamine- induced synovial plasma extravasation is mediated via 5-hydroxytryptamine2A receptors on sympathetic efferent terminals. J Pharmacol Exp Ther 1995;275:502-8
61. Pietraszek MH, Choudhury NA, Koyano K, et al. Enhanced platelet response to serotonin in Buerger's disease. Thromb Res 1990;60:241-6
62. Rydzewski A, Urano T, Hachiya T, et al. The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb Res 1996;84:445-52 (Pubitemid 27033604)
63. Grover-Páez F, Zavalza-Gómez A. Endothelial dysfunction and cardiovascular risk factors. Diabetes Res Clin Pract 2009; 84:1-10
64. Czarnacki M, Zdrojowy K, Adamiec R. Review of current etiopathogenic data of Buerger disease. Pol Merkur Lekarski 2002;13:263-5
65. Foley S, Gibbs H, Muir J. Painful digital infarction in a male smoker treated as Buerger's disease. Australas J Dermatol 2008;49:94-7 (Pubitemid 351537558)
66. Reny JL, Cabane J. Buerger's disease or thromboangiitis Obliterans. Rev Med Interne 1998;19:34-43
67. Harding SA, Sarma J, Josephs DH, et al. Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation 2004;109:1926-9 (Pubitemid 38544479)
68. Neumann FJ, Marx N, Gawaz M, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997;95:2387-94 (Pubitemid 27224733)
69. Lupia E, Bosco O, Goffi A, et al. Thrombopoietin contributes to enhanced platelet activation in cigarette smokers. Atherosclerosis 2010;210:314-9. Epub 20 November 2009
70. Shapiro MF, Greenfield S. The complete blood count and leukocyte differential count. An approach to their rational application. Ann Intern Med 1987;106:65-74 (Pubitemid 17228313)
71. McCarthy DA, Perry JD, Melson RD, Dale MM. Leucocytosis induced by exercise. Br Med J [Clin Res] 1987;295:636 (Pubitemid 17129863)
72. De Stefano V, Za T, Rossi E, et al. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol 2010;85:97-100
73. Tefferi A. Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain. Am J Hematol 2010;85:93-4
74. Nagata M. Inflammatory cells and oxygen radicals. Curr Drug Targets Inflamm Allergy 2005;4:503-4 (Pubitemid 41052417)
75. Csiszar A, Podlutsky A, Wolin MS, Losonczy G, Pacher P, Ungvari Z. Oxidative stress and accelerated vascular aging: implications for cigarette smoking. Front Biosci 2009;14:3128-44
76. Orosz Z, Csiszar A, Labinskyy N, et al. Cigarette smoke-induced proinflammatory alterations in the endothelial phenotype: role of NAD (P)H oxidase activation. Am J Physiol 2007;292: H130-9 (Pubitemid 46105172)
77. Adams MR, Jessup W, Celermajer DS. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J Am Coll Cardiol 1997;29:491-7 (Pubitemid 27116088)
78. Shen Y, Rattan V, Sultana C, Kalra VK. Cigarette smoke condensate-induced adhesion molecule expression and transendothelial migration of monocytes. Am J Physiol 1996;270: H1624-33
79. Shen Y, Rattan V, Sultana C, Kalra VK. Cigarette smoke condensate-induced adhesion molecule expression and transendothelial migration of monocytes. Am J Physiol 1996;270: H1624-33
80. Valavanidis A, Vlachogianni T, Fiotakis K. Tobacco smoke: involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. Int J Environ Res Public Health 2009;6:445-62
81. Scotland RS, Cohen M, Foster P, et al. C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci USA 2005;102:14452-7 (Pubitemid 41429718)
82. Bernhard D, Rossmann A, Henderson B, Kind M, Seubert A, Wick G. Increased serum cadmium and strontium levels in young smokers: effects on arterial endothelial cell gene transcription. Arterioscler Thromb Vasc Biol 2006;26:833-8 (Pubitemid 43732159)
83. Bernhard D, Csordas A, Henderson B, Rossmann A, Kind M, Wick G. Cigarette smoke metal-catalyzed protein oxidation leads to vascular endothelial cell contraction by depolymerization of microtubules. FASEB J 2005;19:1096-107 (Pubitemid 40946435)
84. Blann AD, McCollum CN. Adverse influence of cigarette smoking on the endothelium. Thromb Haemost 1993;70:707-11 (Pubitemid 23310583)
85. Adar R, Papa MZ, Halpern Z, et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med 1983;308: 1113-6 (Pubitemid 13135196)
86. Matsushita M, Nishikimi N, Sakurai T, Nimura Y. Decrease in prevalence of Buerger's disease in Japan. Surgery 1998;124: 498-502 (Pubitemid 28413346)
87. Pertovaara M, Heliövaara M, Raitala A, Oja SS, Knekt P, Hurme M. The activity of the immunoregulatory enzyme indoleamine 2,3-dioxygenase is decreased in smokers. Clin Exp Immunol 2006;145:469-73 (Pubitemid 44252489)
88. Ligam P, Manuelpillai U, Wallace EM, Walker D. Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: implications for role of the kynurenine pathway in pregnancy. Placenta 2005;26: 498-504 (Pubitemid 40796578)
89. Allen E, Barker N, Hines E. Peripheral Vascular Diseases. 4th edn. Philadelphia: WB Saunders, 1972: 326-49
90. Schatz IJ, Fine G, Eyler WR. Thromboangiitis obliterans. Br Heart J 1966;28:84-91
91. Iwai T, Inoue Y, Umeda M, et al. Oral bacteria in the occluded arteries of patients with Buerger disease. J Vasc Surg 2005;42: 107-15 (Pubitemid 40966083)
92. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006;27: 17-23 (Pubitemid 43083560)
93. Mus AM, Cornelissen F, Asmawidjaja PS, et al. Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis. Arthritis Rheum 2010;62:1043-50
94. Morishima N, Mizoguchi I, Takeda K, Mizuguchi J, Yoshimoto T. TGF-beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochem Biophys Res Commun 2009;386:105-10
95. Inomata M, Ishihara Y, Matsuyama T, et al. Degradation of vascular endothelial thrombomodulin by arginine- and lysine-specific cysteine proteases from Porphyromonas gingivalis. J Periodontol 2009;80:1511-7
96. Takahashi Y, Davey M, Yumoto H, Gibson FC III, Genco CA. Fimbria-dependent activation of pro-inflammatory molecules in Porphyromonas gingivalis infected human aortic endothelial cells. Cell Microbiol 2006;8:738-57
97. Amar S, Wu SC, Madan M. Is Porphyromonas gingivalis cell invasion required for atherogenesis? Pharmacotherapeutic implications. J Immunol 2009;182:1584-92
98. Gibson FC III, Genco CA. Porphyromonas gingivalis mediated periodontal disease and atherosclerosis: disparate diseases with commonalities in pathogenesis through TLRs. Curr Pharm Des 2007;13:3665-75
99. Shapira L, Takashiba S, Amar S, Van Dyke TE. Porphyromonas gingivalis lipopolysaccharide stimulation of human monocytes: dependence on serum and CD14 receptor. Oral Microbiol Immunol 1994;9:112-7 (Pubitemid 2060536)
100. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999;274:10689-92
101. Devaney JM, Greene CM, Taggart CC, Carroll TP, O'Neill SJ, McElvaney NG. Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett 2003;544:129-32 (Pubitemid 36628048)
102. Banus S, Stenger RM, Gremmer ER, et al. The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol 2008;9:21
103. Hajishengallis G, Sojar H, Genco RJ, DeNardin E. Intracellular signaling and cytokine induction upon interactions of Porphyromonas gingivalis fimbriae with pattern-recognition receptors. Immunol Invest 2004;33:157-72 (Pubitemid 38685929)
104. Zhang X, Shan P, Qureshi S, et al. Cutting edge: TLR4 deficiency confers susceptibility to lethal oxidant lung injury. J Immunol 2005;175:4834-8 (Pubitemid 41456364)
105. Bachschmid M, Thurau S, Zou MH, Ullrich V. Endothelial cell activation by endotoxin involves superoxide/NO-mediated nitration of prostacyclin synthase and thromboxane receptor stimulation. FASEB J 2003;17:914-6
106. Jayachandran M, Brunn GJ, Karnicki K, Miller RS, Owen WG, Miller VM. In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk. J Appl Physiol 2007;102:429-33 (Pubitemid 46089795)
107. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000;165:618-22 (Pubitemid 30484724)
108. Fleshman K. Buerger's disease in Nepal. Trop Doct 1998;28: 203-6 (Pubitemid 28475137)
109. Nakajima N. The change in concept and surgical treatment on Buerger's disease - personal experience and review. Int J Cardiol 1998;66(Suppl 1):S273-80; discussion S281
110. Meggs WJ. Neurogenic inflammation and sensitivity to environmental chemicals. Environ Health Perspect 1993;101: 234-8
111. Rang HP, Bevan S, Dray A. Chemical activation of nociceptive peripheral neurones. Br Med Bull 1991;47:534-48
112. Junger H, Sorkin LS. Nociceptive and inflammatory effects of subcutaneous TNFalpha. Pain 2000;85:145-51 (Pubitemid 30110754)
113. Shibata M, Ohkubo T, Takahashi H, Inoki R. Interaction of bradykinin with substance P on vascular permeability and pain response. Jpn J Pharmacol 1986;41:427-9 (Pubitemid 16065354)
114. Vrijkotte TG, van Doornen LJ, de Geus EJ. Work stress and metabolic and hemostatic risk factors. Psychosom Med 1999;61:796-805
115. Akassoglou K, Kombrinck KW, Degen JL, Strickland S. Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J Cell Biol 2000;149:1157-66 (Pubitemid 30354264)
116. Choudhury NA, Pietraszek MH, Hachiya T, et al. Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease). Thromb Res 1992;66:321-9
117. Vincenza Carriero M, Franco P, Vocca I, et al. Structure, function and antagonists of urokinase-type plasminogen activator. Front Biosci 2009;14:3782-94
118. Elokdah H, Abou-Gharbia M, Hennan JK, et al. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem 2004;47:3491-4 (Pubitemid 38822010)
119. Musiał J, Wilczyńska M, Sładek K, Cierniewski CS, Nizankowski R, Szczeklik A. Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins 1986; 31:61-70 (Pubitemid 16165375)
120. Chang TC, Huang CJ, Tam K, et al. Stabilization of hypoxia-inducible factor-1{alpha} by prostacyclin under prolonged hypoxia via reducing reactive oxygen species level in endothelial cells. J Biol Chem 2005;280:36567-74 (Pubitemid 41587732)
121. Bozkurt AK, Köksal C, Demirbas MY, et al. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease. Int Angiol 2006;25:162-8 (Pubitemid 44043714)
122. Noël B, Panizzon RG. Use of duplex ultrasonography in the treatment of thromboangiitis obliterans with iloprost. Dermatology 2004;208:238-40
123. Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002;62: 107-33 (Pubitemid 34169428)
124. Katsumura T, Mishima Y, Kamiya K, Sakaguchi S, Tanabe T, Sakuma A. Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo. Angiology 1982;33:357-67 (Pubitemid 12088649)
125. Palomo Arellano A, Gómez Tello V, Parilla Herranz P, Castilla Plaza A, Marcos Sánchez F, Durán Pérez-Navarro A. Buerger's disease starting in the upper extremity. A favorable response to nifedipine treatment combined with stopping tobacco use. An Med Interna 1990;7:307-8
126. Gryglewski RJ. Prostacyclin among prostanoids. Pharmacol Rep 2008;60:3-11 (Pubitemid 351586537)
127. Shimizu Y, Minatoguchi S, Hashimoto K, et al. The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts. J Am Coll Cardiol 2002;40:1347-55
128. Hussein EA, el Dorri A. Intra-arterial streptokinase as adjuvant therapy for complicated Buerger's disease: early trials. Int Surg 1993;78:54-8 (Pubitemid 23119605)
129. Saha K, Chabra N, Gulati SM. Treatment of patients with thromboangiitis obliterans with cyclophosphamide. Angiology 2001;52:399-407 (Pubitemid 32565953)
130. Stone JH. Vasculitis: a collection of pearls and myths. Rheum Dis Clin North Am 2007;33:691-739, v (Pubitemid 350122978)
131. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. Follicular helper T cells: lineage and location. Immunity 2009;30:324-35
132. Ohta T, Shionoya S. Fate of the ischaemic limb in Buerger's disease. Br J Surg 1988;75:259-62
133. Chao W, Olson MS. Platelet-activating factor: receptors and signal transduction. Biochem J 1993;292(Pt 3): 617-29 (Pubitemid 23210185)